Literature DB >> 9301547

Expression of p21WAF1/CIP1 in fetal and adult tissues: simultaneous analysis with Ki67 and p53.

M S Mateo1, A I Saez, M Sanchez-Beato, P Garcia, L Sanchez-Verde, J C Martinez, J L Orradre, M A Piris.   

Abstract

AIMS: To determine the expression of p21WAF1/CIP1 in relation to the expression of Ki67 and p53 in various normal adult and fetal tissues, and to investigate its distribution throughout the cell cycle.
METHODS: The expression of p21WAF1/CIP1 in relation to Ki67 and p53 was analysed in adult and fetal tissues using immunohistochemical techniques. Heat induced epitope retrieval techniques were used to characterise the presence of p21WAF1/CIP1 in different tissues, as well as to detect its distribution throughout the cell cycle. In addition, flow cytometry and western blotting were used to test whether the level of p21WAF1/CIP1 expression varied at different phases of the cell cycle in phytohaemagglutinin (PHA) stimulated lymphocytes.
RESULTS: p21WAF1/CIP1 expression varied from one tissue to another, and it was restricted mainly to the squamous and glandular epithelium, where it appeared in association with p53. Human tissues in which p21WAF1/CIP1 was found showed a mutually exclusive topographical sequential expression between p21WAF1/CIP1 and Ki67. This was confirmed by double labelling studies, which showed that p21WAF1/CIP1 positive cells were in the G0 phase. Unlike these findings of a decline in p21WAF1/CIP1 expression after the G0 phase, PHA stimulated lymphocytes showed a level of p21WAF1/CIP1 expression that rose as the cell progressed through the cell cycle.
CONCLUSIONS: The analysis of p21WAF1/CIP1 expression in relation to the status of p53 should take into account the existence of variable p21WAF1/CIP1 expression in different tissues. This could provide an explanation for the varying frequency of p53 mutations in tumours of different cellular origin. In tissues characterised by regular p21WAF1/CIP1 expression, it appears in a pattern that is consistent with the proposed role of this inhibitor of cyclin dependent kinases in cell cycle arrest-that of inducing cell differentiation. The conflicting results of in vivo and in vitro studies could support the hypothesis that microenvironmental conditions may influence the location of p21WAF1/CIP1 in different phases of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9301547      PMCID: PMC500105          DOI: 10.1136/jcp.50.8.645

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  30 in total

1.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

Review 2.  Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age.

Authors:  T Hunter; J Pines
Journal:  Cell       Date:  1994-11-18       Impact factor: 41.582

3.  Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair.

Authors:  R Li; S Waga; G J Hannon; D Beach; B Stillman
Journal:  Nature       Date:  1994-10-06       Impact factor: 49.962

4.  Induction of p21 (WAF-1/CIP1) during differentiation.

Authors:  R A Steinman; B Hoffman; A Iro; C Guillouf; D A Liebermann; M E el-Houseini
Journal:  Oncogene       Date:  1994-11       Impact factor: 9.867

5.  p21 is a universal inhibitor of cyclin kinases.

Authors:  Y Xiong; G J Hannon; H Zhang; D Casso; R Kobayashi; D Beach
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

6.  Induction of WAF1/CIP1 by a p53-independent pathway.

Authors:  P Michieli; M Chedid; D Lin; J H Pierce; W E Mercer; D Givol
Journal:  Cancer Res       Date:  1994-07-01       Impact factor: 12.701

7.  p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation.

Authors:  W Zhang; L Grasso; C D McClain; A M Gambel; Y Cha; S Travali; A B Deisseroth; W E Mercer
Journal:  Cancer Res       Date:  1995-02-01       Impact factor: 12.701

8.  The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA.

Authors:  S Waga; G J Hannon; D Beach; B Stillman
Journal:  Nature       Date:  1994-06-16       Impact factor: 49.962

9.  p21-containing cyclin kinases exist in both active and inactive states.

Authors:  H Zhang; G J Hannon; D Beach
Journal:  Genes Dev       Date:  1994-08-01       Impact factor: 11.361

10.  p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.

Authors:  V Dulić; W K Kaufmann; S J Wilson; T D Tlsty; E Lees; J W Harper; S J Elledge; S I Reed
Journal:  Cell       Date:  1994-03-25       Impact factor: 41.582

View more
  5 in total

1.  Unique phenotypic profile of monocytoid B cells: differences in comparison with the phenotypic profile observed in marginal zone B cells and so-called monocytoid B cell lymphoma.

Authors:  F I Camacho; J F García; L Sánchez-Verde; A I Sáez; M Sánchez-Beato; M Mollejo; M A Piris
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Expression of p53 and Ki-67 antigen in bone marrow giant proerythroblasts associated with human parvovirus B19 infection.

Authors:  Y Sadahira; T Sugihara; Y Yawata
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

3.  p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer.

Authors:  M A Anttila; V M Kosma; J Hongxiu; J Puolakka; M Juhola; S Saarikoski; K Syrjänen
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

4.  Relationship between expression of p21WAF1/CIP1 and radioresistance in human gliomas.

Authors:  T Kokunai; N Tamaki
Journal:  Jpn J Cancer Res       Date:  1999-06

5.  Lack of Cell Cycle Inhibitor p21 and Low CD4+ T Cell Suppression in Newborns After Exposure to IFN-β.

Authors:  Jop Jans; Wendy W Unger; Elisabeth A M Raeven; Elles R Simonetti; Marc J Eleveld; Ronald de Groot; Marien I de Jonge; Gerben Ferwerda
Journal:  Front Immunol       Date:  2021-04-12       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.